You are here
Aeglea BioTherapeutics to Present at 2018 Wells Fargo Healthcare Conference
Company to Webcast Presentation on Wednesday, September 5 at 10:50 am ET
AUSTIN, Texas, Aug. 28, 2018 (GLOBE NEWSWIRE) -- Aeglea BioTherapeutics, Inc. (NASDAQ:AGLE), a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer, today announced that it will present a corporate overview at the 2018 Wells Fargo 13th Annual Healthcare Conference, being held on September 5-6 in Boston, MA.
|Wells Fargo Healthcare Conference|
|Aeglea BioTherapeutics Presentation Details|
|Date:||Wednesday, September 5|
|Time:||10:50 am Eastern Time|
|Location:||The Westin Copley Place, Boston, MA|
To access the live and archived webcast of the presentation, please visit the Presentations & Events section of the Aeglea BioTherapeutics investor relations website. Please connect to the website at least 15 minutes prior to the presentation to allow for any software download that may be necessary. The replay of the webcast will be available for 30 days thereafter.
Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Aeglea’s Compensation Committee of its Board of Directors has granted non-qualified stock options to purchase an aggregate of 41,000 shares of Aeglea’s common stock to four new employees under Aeglea’s 2018 Equity Inducement Plan. The 2018 Equity Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Aeglea (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Aeglea, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules. The options have an exercise price of $10.28 or $10.54 per share, which is equal to the closing price of Aeglea’s common stock on August 24, 2018 or August 27, 2018, respectively. Each of the option awards vests as to 25% of the shares on the one-year anniversary of its grant, with the remainder of the shares vesting ratably over 36 months thereafter.
About Aeglea BioTherapeutics
Aeglea is a clinical-stage biotechnology company that designs and develops innovative human enzyme therapeutics for patients with rare genetic diseases and cancer. Aeglea is developing pegzilarginase, its lead investigational therapy, for the treatment of Arginase 1 Deficiency, as monotherapy in arginine-dependent cancers and in combination with an immune checkpoint inhibitor for small cell lung cancer. In addition, Aeglea has an active research pipeline of other human enzyme-based approaches in both therapeutic areas. For more information, please visit http://aegleabio.com.
Sharon Merrill Associates
Director, Finance & Investor Relations